Gene: EGFR ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE Here, we report the case of a 72-year-old, never-smoker female diagnosed with multiple metastatic lung adenocarcinoma (cT2aN2M1) harboring EGFR mutations in exon 21 (L858R) of the primary lesion. 30022837

2018
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE Here, we report the case of a 72-year-old, never-smoker female diagnosed with multiple metastatic lung adenocarcinoma (cT2aN2M1) harboring EGFR mutations in exon 21 (L858R) of the primary lesion. 30022837

2018
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE Here, we report the case of a 72-year-old, never-smoker female diagnosed with multiple metastatic lung adenocarcinoma (cT2aN2M1) harboring EGFR mutations in exon 21 (L858R) of the primary lesion. 30022837

2018
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.030 GeneticVariation BEFREE Transabdominal hysterectomy and bilateral salpingo-oophorectomy showed solitary intramyometrial metastatic lung adenocarcinoma with a second-site T790M gatekeeper mutation in exon 20 of the EGFR gene. 29094453

2018
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. 24453288

2014
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218

2014
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. 24453288

2014
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218

2014
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. 24453288

2014
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218

2014
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.030 GeneticVariation BEFREE Genetic testing revealed two additional EGFR T790M germline carriers, one of which was subsequently diagnosed with metastatic lung adenocarcinoma. 24736080

2014
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.030 GeneticVariation BEFREE In this article we present a case of a patient suffering from a metastatic lung adenocarcinoma with an activating mutation on diagnosis, initially responding to treatment with erlotinib, who subsequently developed a secondary resistance due to acquiring the T790M mutation in exon 20 of the EGFR gene. 20678850

2011